Gemoab Monoclonals Gmbh competitive analysis

Explore patent oppositions filed by Gemoab Monoclonals Gmbh against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Universal Anti-Tag Chimeric Antigen Receptor-Expressing T Cells And Methods Of Treating CancerUNIVERSITY OF MARYLANDJan 20, 2021

Latest PTAB cases involving Gemoab Monoclonals Gmbh

Discover the latest PTAB cases involving Gemoab Monoclonals Gmbh, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 27, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Gemoab Monoclonals Gmbh

IPR2020-00233Dec 20, 2019GEMOAB MONOCLONALS GMBHUNIVERSITY OF MARYLANDInstitution Denied

Peer Comparison New

IP litigation analysis comparing Gemoab Monoclonals Gmbh with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GEMOAB MONOCLONALS GMBH1 - 1 -
UNIVERSITY OF MARYLAND - 5 - 2